All In Biotech

Drug Trial Radar · NCT02441218

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Last checked: Nov 19, 2026Latest source record: Jan 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,505 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,505

Actual

Start

Sep 2006

Primary completion

Apr 2010

Study completion Apr 2010

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate the superiority of ivabradine over placebo in the reduction of cardiovascular mortality or hospitalisation for worsening heart failure in patients with moderate to severe symptoms of chronic heart failure, a reduced left ventricular ejection fraction and currently receiving recommended therapy for this disease.

Conditions

  • Chronic Heart Failure

Interventions

  • IvabradineDrug

    2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.

  • PlaceboDrug

    Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure.Time frame: All over the study (up to 42 months).

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Hôpital Pitié-Salpétrière

    Paris, France

  • Göteborg University

    Gothenburg, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.